+

WO1994024279A3 - Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques - Google Patents

Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques Download PDF

Info

Publication number
WO1994024279A3
WO1994024279A3 PCT/EP1994/001164 EP9401164W WO9424279A3 WO 1994024279 A3 WO1994024279 A3 WO 1994024279A3 EP 9401164 W EP9401164 W EP 9401164W WO 9424279 A3 WO9424279 A3 WO 9424279A3
Authority
WO
WIPO (PCT)
Prior art keywords
huntington
disease
agents
prevention
treatment
Prior art date
Application number
PCT/EP1994/001164
Other languages
English (en)
Other versions
WO1994024279A2 (fr
Inventor
Johanna Eugenie Bergmann
Rick E Preddie
Original Assignee
Johanna Eugenie Bergmann
Rick E Preddie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA 2094169 external-priority patent/CA2094169A1/fr
Application filed by Johanna Eugenie Bergmann, Rick E Preddie filed Critical Johanna Eugenie Bergmann
Priority to AU66781/94A priority Critical patent/AU6678194A/en
Publication of WO1994024279A2 publication Critical patent/WO1994024279A2/fr
Publication of WO1994024279A3 publication Critical patent/WO1994024279A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des agents et des méthodes pour le diagnostic et la thérapie de la chorée de Huntington et de pathologies associées. Lesdits agents contiennent des molécules antisens de gènes impliqués dans la chorée de Huntington et les maladies associées, des analogues et des dérivés de ces molécules, ainsi que des molécules protéiniques exprimées par ces gènes.
PCT/EP1994/001164 1993-04-16 1994-04-14 Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques WO1994024279A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU66781/94A AU6678194A (en) 1993-04-16 1994-04-14 Agents for the prevention and treatment of huntington's disease and other neurological disorders

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CA 2094169 CA2094169A1 (fr) 1993-04-16 1993-04-16 Agents de prevention et de traitement de la maladie d'huntington chez les humains: adn-c, hormone polypeptidique agissant comme precurseur et hormone active reconstituee a partir d'un brin anti-sens du gene de la maladie d'huntington, le "huntingtin"
CA2,094,169 1993-04-16
US5057893A 1993-04-20 1993-04-20
US08/050,578 1993-04-20

Publications (2)

Publication Number Publication Date
WO1994024279A2 WO1994024279A2 (fr) 1994-10-27
WO1994024279A3 true WO1994024279A3 (fr) 1995-03-30

Family

ID=25676093

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1994/001164 WO1994024279A2 (fr) 1993-04-16 1994-04-14 Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques

Country Status (2)

Country Link
AU (1) AU6678194A (fr)
WO (1) WO1994024279A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5741645A (en) * 1993-06-29 1998-04-21 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
US5834183A (en) * 1993-06-29 1998-11-10 Regents Of The University Of Minnesota Gene sequence for spinocerebellar ataxia type 1 and method for diagnosis
WO1997006313A1 (fr) 1995-08-03 1997-02-20 Europa Metalli S.P.A. Elements de plomberie a faible liberation de plomb constitues d'alliages a base de cuivre contenant du plomb et procede de fabrication correspondant
US6093549A (en) * 1995-11-09 2000-07-25 The Johns Hopkins University Huntingtin-associated protein-related assays
CA2238075A1 (fr) * 1995-11-17 1997-05-29 The University Of British Columbia Proteine ayant une interaction avec le gene de la maladie de huntington, adnc codant cette proteine et anticorps contre celle-ci
CA2410120A1 (fr) * 1996-08-28 1998-03-05 The Johns Hopkins University School Of Medicine Procede de detection de dereglements proliferatifs cellulaires

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BERGMANN, J.E. ET AL.: "A protein drp90 encoded on the leftwards strand of soybean nodule urate oxidase cDNA ...", NUCLEIC ACIDS RESEARCH, vol. 19, no. 6, 1991, pages 1338 *
PREDDIE, E. & BERGMANN, J.E.: "A novel protein (suef) programmed by the leftwards starnd of a chimeric cDNA stops the expression of several proteins in E.coli", NUCLEIC ACIDS RESEARCH, vol. 18, no. 21, 1990, pages 6459 *
THE HUNTINGTON'S DESEASE COLLABORATIVE RESEARCH GROUP: "A novel gene containing a trinucleotide repeat that is expanded and unstable in Huntington's disease chromosomes", CELL, vol. 72, 26 March 1993 (1993-03-26), pages 971 - 983 *

Also Published As

Publication number Publication date
WO1994024279A2 (fr) 1994-10-27
AU6678194A (en) 1994-11-08

Similar Documents

Publication Publication Date Title
WO2001009118A3 (fr) Composes dithiolthione pour le traitement de troubles neurologiques et pour renforcer la memoire
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
WO1999064059A3 (fr) Utilisation de la secretine pour le traitement de l'autisme et d'autres troubles du comportement, troubles neurologiques ou immunologiques
TW264480B (fr)
AU6406996A (en) Compositions for the treatment and diagnosis of body weight disorders, including obesity
AU4239196A (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
WO1997002046A3 (fr) Conjugues de saccharide
IL135315A0 (en) 4(3)-substituted-4(3)-aminomethyl-(thio)pyran or -piperidine derivatives (gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO1997034586A3 (fr) Dispositif et methode de traitement de maladies ophtalmiques
HUP0004439A3 (en) 1-substituted-1-aminomethyl-cycloalkane derivatives (=gabapentin analogues), their preparation and their use in the treatment of neurological disorders
WO2001083729A3 (fr) Vecteurs pour transduction oculaire et utilisation en therapie genique
AU3497295A (en) Compositions and methods for the treatment of body weight disorders, including obesity
CA2223776A1 (fr) Procede de traitement de maladies pulmonaires au moyen d'oligonucleotides antisens
WO2004110360A3 (fr) Mutants de degradation du proteoglycane pour le traitement du systeme nerveux central
WO2002096415A3 (fr) Procedes pour traiter la maladie d'alzheimer et/ou pour reguler les niveaux de peptides beta-amyloides chez un sujet
WO2002036829A3 (fr) Procedes de diagnostic de prevention et de traitement de troubles neurologiques et de lesions neuronales
EP0331620A3 (en) Agent for the treatment of parkinson's disease
WO2003034996A3 (fr) Utilisation de leptine pour traiter la lipoatrophie humaine et procede pour determiner une predisposition a ce traitement
WO2000018316A3 (fr) Composition ophtalmique agreable, a liberation prolongee, et procede de therapie oculaire
TW200640944A (en) VGF polypeptides and methods of treating VGF-related disorders
AU3364499A (en) Method for delaying the onset of alzheimer's disease and for treating or delaying the onset of other amyloidosis-related diseases/disorders
AU4312593A (en) Use of indolone derivatives for the treatment of memory disorders, sexual dysfunction and Parkinson's disease
WO1994024279A3 (fr) Agents pour la prevention et le traitement de la choree de huntington et d'autres troubles neurologiques
IT1290781B1 (it) Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
WO2000009098A3 (fr) Methode de traitement de maladies oculaires neovasculaires

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1994914374

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1994914374

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载